Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile GnRH Therapy for Male Pituitary Stalk Interruption Syndrome
NCT02705014Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gonadorelin in Pituitary stalk interruption syndrome (PSIS), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change of serum Luteinizing Hormone value at 12 months, Change of serum Follicle-Stimulating Hormone value at 12 months and 1 more. Status: unknown.
02
Drugs
gonadorelin
03
Conditions
Pituitary stalk interruption syndrome (PSIS)
Beyond the preview
Go deeper on NCT02705014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705014.